Enhancing selectivity of novel outer-selective hollow fiber forward osmosis membrane by polymer nanostructures

Extracellular Vesicles
/References

Sanahuja-Embuena, V., Lim, S., Górecki, R., Trzaskus, K., Hélix-Nielsen, C. and Kyong Shon, H., 2021. Enhancing selectivity of novel outer-selective hollow fiber forward osmosis membrane by polymer nanostructures. Chemical Engineering Journal, p.133634.

An ideal forward osmosis (FO) membrane module for osmotic membrane bioreactor (OMBR) application would have high packing density, low reverse solute flux and low fouling propensity. Recently, an outer-selective hollow fiber forward osmosis (HFFO) membrane has been developed to simultaneously improve packing density and reduce fouling propensity. However, a high reverse solute flux of the HFFO membrane still generates a salinity build-up in the reactor and remains the main challenge of this technology. To tackle this problem, we successfully improved the selectivity of an outer-selective HFFO membrane by incorporating a prior developed formulation based on Pluronic® nanostructures containing water selective proteins into the active layer of the membrane. The assimilation of these nanostructures in the membrane resulted in a significant decrease of the specific reverse solute flux from 0.36 ± 0.01 gL-1 to 0.12 ± 0.02 gL-1 with no significant decrease in water flux. Also, urea was selected as a challenging solute to investigate the selectivity of the developed membranes. In comparison with the pristine membranes, membranes containing nanostructures presented a superior rejection of urea from 87.7 ± 2.0 % to 95.2 ± 0.9 %. The developed membranes are able to be used for future OMBR application tests to prove feasibility of the process. Thus, this study can lead to the development of new membranes suitable for efficient and long-term operation in OMBR configurations. Additionally, the nanostructures investigated here can be used for different thin-film composite membranes as an additive to improve membrane selectivity.

View full article

Recent Publications

Cigarette smoke (CS) represents one of the most relevant environmental risk factors for several chronic pathologies. Tissue damage caused by CS exposure is mediated, at least in part, by oxidative stress induced by its toxic and pro-oxidant components. Evidence demonstrates that extracellular vesicles (EVs) released by various cell types exposed to CS extract (CSE) are characterized by altered biochemical cargo and gained pathological properties. In the present study, we evaluated the content of oxidized proteins and phospholipid fatty acid profiles of EVs released by human bronchial epithelial BEAS-2B cells treated with CSE. This specific molecular characterization has hitherto not been performed. After confirmation that CSE reduces viability of BEAS-2B cells and elevates intracellular ROS levels, in a dose-dependent manner, we demonstrated that 24 h exposure at 1% CSE, a concentration that only slight modifies cell viability but increases ROS levels, was able to increase carbonylated protein levels in cells and released EVs. The release of oxidatively modified proteins via EVs might represent a mechanism used by cells to remove toxic proteins in order to avoid their intracellular overloading. Moreover, 1% CSE induced only few changes in the fatty acid asset in BEAS-2B cell membrane phospholipids, whereas several rearrangements were observed in EVs released by CSE-treated cells. The impact of changes in acyl chain composition of CSE-EVs accounted for the increased saturation levels of phospholipids, a membrane parameter that might influence EV stability, uptake and, at least in part, EV-mediated biological effects. The present in vitro study adds new information concerning the biochemical composition of CSE-related EVs, useful to predict their biological effects on target cells. Furthermore, the information regarding the presence of oxidized proteins and the specific membrane features of CSE-related EVs can be useful to define the utilization of circulating EVs as marker for diagnosing of CS-induced lung damage and/or CS-related diseases.

2023
No items found.
No items found.
No items found.